Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Clinical Therapeutics

Low Central Nervous System Posaconazole Concentrations during Cerebral Phaeohyphomycosis

François Barde, Eliane Billaud, Lauriane Goldwirt, Catherine Horodyckid, Vincent Jullien, Fanny Lanternier, Philippe Lesprit, Lucie Limousin, Jérémie F. Cohen, Olivier Lortholary
François Barde
aNecker-Pasteur Center for Infectious Diseases and Tropical Medicine, Necker-Enfants Malades Hospital, AP-HP, Paris Descartes University, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eliane Billaud
bLaboratory of Pharmacology and Toxicology, European Hospital Georges Pompidou, AP-HP, Paris Descartes University, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauriane Goldwirt
cDepartment of Pharmacology, Saint-Louis Hospital, AP-HP, Paris Diderot University, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Horodyckid
dDepartment of Neurosurgery, Foch Hospital, Suresnes, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent Jullien
bLaboratory of Pharmacology and Toxicology, European Hospital Georges Pompidou, AP-HP, Paris Descartes University, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fanny Lanternier
aNecker-Pasteur Center for Infectious Diseases and Tropical Medicine, Necker-Enfants Malades Hospital, AP-HP, Paris Descartes University, Paris, France
eInstitut Pasteur, Molecular Mycology Unit, National Reference Center for Invasive Mycoses and Antifungals, CNRS UMR 2000, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe Lesprit
fDepartment of Clinical Biology, Foch Hospital, Suresnes, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucie Limousin
gDepartment of Microbiology, Foch Hospital, Suresnes, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jérémie F. Cohen
aNecker-Pasteur Center for Infectious Diseases and Tropical Medicine, Necker-Enfants Malades Hospital, AP-HP, Paris Descartes University, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jérémie F. Cohen
Olivier Lortholary
aNecker-Pasteur Center for Infectious Diseases and Tropical Medicine, Necker-Enfants Malades Hospital, AP-HP, Paris Descartes University, Paris, France
eInstitut Pasteur, Molecular Mycology Unit, National Reference Center for Invasive Mycoses and Antifungals, CNRS UMR 2000, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.01184-19
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Posaconazole diffusion has been documented in various organs, which contrasts with the scarce data available for the human central nervous system (CNS). We analyzed posaconazole concentrations in plasma and multiple CNS specimens taken from a patient who received posaconazole because of cerebral phaeohyphomycosis. Low posaconazole concentrations were obtained in CNS specimens, with sample-to-plasma ratios between 5% and 22%. This case highlights the role of neurosurgery during cerebral phaeohyphomycoses, even those caused by posaconazole-susceptible black fungi.

TEXT

Posaconazole is a broad-spectrum triazole antifungal agent used for prophylaxis of invasive fungal infections (IFIs) among high-risk hematology patients and as salvage therapy of IFIs such as invasive aspergillosis (1, 2). However, available data regarding central nervous system (CNS) diffusion of posaconazole are scarce. There is no published report of in vivo CNS measurements of posaconazole in humans, except in cerebrospinal fluid (CSF).

In 2018, a woman in her 50s with a history of Crohn’s disease treated with corticosteroids, azathioprine, and mesalazine was seen in the emergency room because of progressive headaches associated with vertigo, anterograde amnesia, dysphasia, and pain of the left upper limb. She was afebrile, alert, and experiencing expressive aphasia. The patient had an otherwise unremarkable clinical evaluation. Her blood count showed 5,100 leukocytes/mm3, and her C-reactive protein level was 12.9 mg/dl. Noncontrasted cerebral computed tomography (CT) showed left parietotemporal cystic lesions associated with vasogenic edema and left uncal herniation.

The patient was admitted for further investigation. CSF analysis was unremarkable. Serum and CSF Aspergillus galactomannan antigen tests were negative. Serum and CSF β-d-glucan levels were 313 and >500 pg/ml, respectively. A keyhole aspiration of the main lesion was carried out, with the evacuation of a small amount of creamy greenish pus. Direct microscopic examination of the aspiration fluid stained with Gram and hematoxylin-eosin revealed several moniliform hyphal structures. Pus was seeded onto blood agar, chocolate agar (PolyViteX), Coletsos agar, Sabouraud agar, Schaedler agar, and Schaedler broth supplemented with 0.02% vitamin K. Voriconazole (6 mg/kg twice-daily loading dose followed by 4 mg/kg intravenous [i.v.] twice daily) was started because of suspected invasive Aspergillus infection. After 13 days of incubation at 35°C, black fungi appeared, and cultures were sent to the French National Reference Center for Mycoses and Antifungals (Institut Pasteur, Paris, France).

Postcontrast axial T1-weighted brain magnetic resonance imaging (MRI) showed one large left parietotemporal rim-enhancing polycyclic lesion with partial lateral sinus thrombosis (Fig. 1A). Axial diffusion-weighted MRI showed increased signal intensity with low apparent diffusion coefficient, suggesting abscesses. On the basis of morphological features, the fungus was identified as Rhinocladiella mackenziei, which was confirmed by nucleotide sequence analysis of the internal transcribed spacer and the 28S ribosomal subunit (3). After the identification, the patient was switched to posaconazole (300 mg i.v. once daily, which was then secondarily increased to 400 mg i.v. once daily because of insufficient trough concentration). Posaconazole plasma concentrations were monitored once a week, aiming at trough concentrations between 2,000 and 5,000 ng/ml.

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Postcontrast axial T1-weighted MRI images. (A) Rim-enhancing left temporal lesion with central hypointensity (baseline). (B) Postsurgical cavity with decreased perilesional edema (3 months after surgery).

One month after the initial keyhole aspiration, the patient underwent neurosurgery. The abscess shell was particularly rigid. About 97% of the brain abscess was surgically removed, with a small residual lesion remaining in the left transversal sinus. There was no intraoperative complication. During surgery, several samples were taken for posaconazole concentration measurement in plasma, superficial brain parenchyma, abscess pus, surgical piece, meninges, and CSF (lumbar puncture was contraindicated because of the risk of temporal herniation).

Plasma and CSF posaconazole concentrations were measured using routine liquid chromatography-mass spectrometry (LC-MS). Purification sample preparation of both plasma and CSF (50 μl) was conducted using acetonitrile for protein precipitation. After centrifugation, 5 μl of the supernatant was injected into the LC-MS/MS system (Waters Acquity UPLC-TQD system, Milford, MA). The chromatographic separation was performed on a C18 BEH column. The calibration range was from 200 to 5,000 ng/ml (Chromsystems). Other CNS samples were stored at –80°C before analysis. Brain samples were accurately weighed, homogenized in phosphate-buffered saline 1X using Precellys 24 (Bertin Technologies, Montigny-le-Bretonneux, France), and then quantified by LC-MS. Posaconazole concentration measurements are reported in Table 1.

View this table:
  • View inline
  • View popup
TABLE 1

Posaconazole concentrations in central nervous system

A couple of days after surgery, the patient was conscious and had stable neurological status. The patient was discharged 4 weeks after neurosurgery, and treatment by posaconazole (400 mg oral once daily) was continued. Three months after surgery, the patient showed almost complete neurological recovery except for a slight word-finding difficulty. MRI showed a postsurgical cavity with decreased perilesional edema and persistent partial lateral sinus thrombosis (Fig. 1B). Posaconazole was well tolerated, with transient paresthesia appearing as the sole potential related adverse event.

To our knowledge, this is the first case summary that reports on simultaneous posaconazole measurement performed in various CNS tissues in vivo in humans, including cerebral parenchyma. Posaconazole concentrations obtained in CSF and all CNS specimens were low compared with plasma concentrations, with a sample-to-plasma ratio of 8% for CSF and between 5% and 22% for cerebral tissues.

A huge variability in the CNS diffusion of posaconazole was previously reported, with an average CSF-to-plasma ratio of 0.57% in a patient with hematopoietic stem cell transplantation with pulmonary aspergillosis (4), 40% to 50% in a patient with cerebral abscesses, and 230% in a patient with bacterial meningitis and cerebral aspergillosis (5). Based on these reports, alteration of the blood-brain barrier (BBB) appears to be a major determinant of the diffusion of posaconazole into CSF. However, this diffusion was only 8% in our patient, despite the local fungal infection likely increasing the permeability of the BBB.

Regarding diffusion into brain tissues, the tissue-to-plasma ratios presently observed were lower than the values of ∼100% that were retrieved in biopsy specimens taken at autopsy from seven patients under posaconazole prophylaxis after allogeneic stem cell transplantation (6). Nevertheless, a postmortem change in the diffusion of posaconazole across the BBB cannot be excluded.

Compared to animal studies, our findings suggest lower CNS penetration of posaconazole in humans than in murine models of invasive fungal infection. For example, Calvo et al. (7) showed a dose-dependent efficacy of posaconazole in reducing the fungal load in cerebral phaeohyphomycosis due to Fonsecaea monophora and a posaconazole brain tissue-to-serum concentration ratio of between 39% and 69%.

The diffusion and concentration of triazoles in the CNS depend on several factors, such as molecular weight and structure, lipophilicity, local inflammation, mechanisms of active efflux, and protein binding (8, 9). Posaconazole has a high degree of structural similarity to itraconazole and a rather high molecular weight (∼700 Da) combined with extensive binding to plasma proteins (>98%), which would predict poor CNS penetration. However, posaconazole lipophilicity is close to that of voriconazole, another triazole that can achieve concentrations in CNS tissue much higher than in CSF and higher than would be anticipated from the unbound fraction (9). It remains unclear whether P-glycoprotein, which mediates active efflux of itraconazole at the level of the BBB, can also induce posaconazole active efflux from the brain (10).

Our patient was treated by combining surgery and posaconazole treatment, which was previously shown to be an effective antimicrobial agent in the treatment of CNS fungal infection (11, 12), especially in this kind of phaeohyphomycosis infection (3, 13). Despite evidence of low posaconazole concentrations in her CNS samples, the patient showed rapid and steady clinical improvement after surgery. This suggests that, whereas posaconazole might remain the best triazole agent to use in patients with CNS invasive phaeohyphomycosis, prompt and extensive neurosurgical treatment is critical in the management of such patients.

ACKNOWLEDGMENTS

Informed consent was obtained from the patient to use her medical information and specimens for medical and scientific purposes aiming at improving medical knowledge and patient care. All samples and data were obtained as part of routine care. There was no specific Institutional Review Board (IRB) approval.

We thank Baptiste Lafont-Rapnouil for assistance during surgery.

We have no conflicts of interest to report.

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

FOOTNOTES

    • Received 9 June 2019.
    • Returned for modification 1 July 2019.
    • Accepted 15 July 2019.
    • Accepted manuscript posted online 19 August 2019.
  • Copyright © 2019 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Cornely OA,
    2. Maertens J,
    3. Winston DJ,
    4. Perfect J,
    5. Ullmann AJ,
    6. Walsh TJ,
    7. Helfgott D,
    8. Holowiecki J,
    9. Stockelberg D,
    10. Goh YT,
    11. Petrini M,
    12. Hardalo C,
    13. Suresh R,
    14. Angulo-Gonzalez D
    . 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356:348–359. doi:10.1056/NEJMoa061094.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Walsh TJ,
    2. Raad I,
    3. Patterson TF,
    4. Chandrasekar P,
    5. Donowitz GR,
    6. Graybill R,
    7. Greene RE,
    8. Hachem R,
    9. Hadley S,
    10. Herbrecht R,
    11. Langston A,
    12. Louie A,
    13. Ribaud P,
    14. Segal BH,
    15. Stevens DA,
    16. van Burik JA,
    17. White CS,
    18. Corcoran G,
    19. Gogate J,
    20. Krishna G,
    21. Pedicone L,
    22. Hardalo C,
    23. Perfect JR
    . 2007. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 44:2–12. doi:10.1086/508774.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Cristini A,
    2. Garcia-Hermoso D,
    3. Celard M,
    4. Albrand G,
    5. Lortholary O
    . 2010. Cerebral phaeohyphomycosis caused by Rhinocladiella mackenziei in a woman native to Afghanistan. J Clin Microbiol 48:3451–3454. doi:10.1128/JCM.00924-10.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Reinwald M,
    2. Uharek L,
    3. Lampe D,
    4. Grobosch T,
    5. Thiel E,
    6. Schwartz S
    . 2009. Limited penetration of posaconazole into cerebrospinal fluid in an allogeneic stem cell recipient with invasive pulmonary aspergillosis. Bone Marrow Transplant 44:269–270. doi:10.1038/bmt.2009.17.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Ruping MJ,
    2. Albermann N,
    3. Ebinger F,
    4. Burckhardt I,
    5. Beisel C,
    6. Muller C,
    7. Vehreschild JJ,
    8. Kochanek M,
    9. Fatkenheuer G,
    10. Bangard C,
    11. Ullmann AJ,
    12. Herr W,
    13. Kolbe K,
    14. Hallek M,
    15. Cornely OA
    . 2008. Posaconazole concentrations in the central nervous system. J Antimicrob Chemother 62:1468–1470. doi:10.1093/jac/dkn409.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Blennow O,
    2. Eliasson E,
    3. Pettersson T,
    4. Pohanka A,
    5. Szakos A,
    6. El-Serafi I,
    7. Hassan M,
    8. Ringdén O,
    9. Mattsson J
    . 2014. Posaconazole concentrations in human tissues after allogeneic stem cell transplantation. Antimicrob Agents Chemother 58:4941–4943. doi:10.1128/AAC.03252-14.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Calvo E,
    2. Pastor FJ,
    3. Rodriguez MM,
    4. Mayayo E,
    5. Salas V,
    6. Guarro J
    . 2010. Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. Antimicrob Agents Chemother 54:919–923. doi:10.1128/AAC.01284-09.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Stott KE,
    2. Hope W
    . 2018. Pharmacokinetics-pharmacodynamics of antifungal agents in the central nervous system. Expert Opin Drug Metab Toxicol 14:803–815. doi:10.1080/17425255.2018.1492551.
    OpenUrlCrossRef
  9. 9.↵
    1. Felton T,
    2. Troke PF,
    3. Hope WW
    . 2014. Tissue penetration of antifungal agents. Clin Microbiol Rev 27:68–88. doi:10.1128/CMR.00046-13.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Miyama T,
    2. Takanaga H,
    3. Matsuo H,
    4. Yamano K,
    5. Yamamoto K,
    6. Iga T,
    7. Naito M,
    8. Tsuruo T,
    9. Ishizuka H,
    10. Kawahara Y,
    11. Sawada Y
    . 1998. P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. Antimicrob Agents Chemother 42:1738–1744. doi:10.1128/AAC.42.7.1738.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Pitisuttithum P,
    2. Negroni R,
    3. Graybill JR,
    4. Bustamante B,
    5. Pappas P,
    6. Chapman S,
    7. Hare RS,
    8. Hardalo CJ
    . 2005. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 56:745–755. doi:10.1093/jac/dki288.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Kim MM,
    2. Vikram HR,
    3. Kusne S,
    4. Seville MT,
    5. Blair JE
    . 2011. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole. Clin Infect Dis 53:1060–1066. doi:10.1093/cid/cir642.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Al-Abdely HM,
    2. Alkhunaizi AM,
    3. Al-Tawfiq JA,
    4. Hassounah M,
    5. Rinaldi MG,
    6. Sutton DA
    . 2005. Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole. Med Mycol 43:91–95. doi:10.1080/13693780400011104.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Low Central Nervous System Posaconazole Concentrations during Cerebral Phaeohyphomycosis
François Barde, Eliane Billaud, Lauriane Goldwirt, Catherine Horodyckid, Vincent Jullien, Fanny Lanternier, Philippe Lesprit, Lucie Limousin, Jérémie F. Cohen, Olivier Lortholary
Antimicrobial Agents and Chemotherapy Oct 2019, 63 (11) e01184-19; DOI: 10.1128/AAC.01184-19

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Low Central Nervous System Posaconazole Concentrations during Cerebral Phaeohyphomycosis
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Low Central Nervous System Posaconazole Concentrations during Cerebral Phaeohyphomycosis
François Barde, Eliane Billaud, Lauriane Goldwirt, Catherine Horodyckid, Vincent Jullien, Fanny Lanternier, Philippe Lesprit, Lucie Limousin, Jérémie F. Cohen, Olivier Lortholary
Antimicrobial Agents and Chemotherapy Oct 2019, 63 (11) e01184-19; DOI: 10.1128/AAC.01184-19
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

invasive fungal infections
antifungal therapy
plasma drug levels
therapeutic drug monitoring
Rhinocladiella mackenziei
cerebral phaeohyphomycosis

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596